nach oben

Journal of Immigrant and Minority Health

Erschienen in:

25.05.2018 | Original Paper

Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community

Erschienen in: Journal of Immigrant and Minority Health | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Hepatitis C treatment has rapidly evolved with the arrival of direct-acting antiviral therapy. Sustained virologic response (SVR) rates in clinical trials are high but it is unknown how this translates to the immigrant community. Data from December 2013 to September 2015 was collected from a Midwest academic and community practice with a large immigrant population. There were 802 patients with an overall SVR rate of 88%. Ledipasvir/sofosbuvir was associated with favorable response among genotype 1 and 4 patients compared to other regimens (p < 0.001 and p = 0.05). Factors associated with treatment failure included advanced liver disease, male gender, East African/Middle Eastern ethnicity, and non-compliance. Patients with genotype 4 had lower SVR rates than other genotypes (58% vs. 89%, p < 0.001), particularly among East Africans (40% vs. 82% for other ethnicities). Our SVR rate for genotype 4 infection is lower than clinical trials and may be related to cultural, biologic and socioeconomic factors.

Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014;109(5):628–35.CrossRefPubMed

Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.CrossRefPubMed

Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–603.CrossRefPubMed

Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–92.CrossRefPubMed

Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65.CrossRefPubMed

Zeuzem S, Dusheiko DM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.CrossRefPubMed

Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.CrossRefPubMed

Jacobson IM, Gordon SC, Kowdley KW, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77.CrossRefPubMed

Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.CrossRefPubMed

10.

Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385(9973):1098–106.CrossRefPubMed

11.

U.S. Census Bureau (2010). The foreign-born population from Africa: 2008–2012. https://www.census.gov/content/dam/Census/library/publications/ 2014/acs/acsbr12-16.pdf. Accessed 11 Dec 2015

12.

Lopez-Velez R, Turrientes C, Guiterriez C, Mateos M. Prevalence of hepatitis B, C, and D markers in Sub-Saharan African immigrants. J Clin Gastroenterol. 1997;25(4):650–2.CrossRefPubMed

13.

Shire AM, Sandhu DS, Kaiya JK, et al. Viral hepatitis among somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proceed. 2012;87(1):17–24.CrossRef

14.

U.S Census Bureau (2010). The Asian population: 2010. https://www.census.gov/prod/cen2010/briefs/c2010br-11.pdf. Accessed 11 Dec 2015

15.

Kamal SA, Nasser IA. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology. 2008;47(4):1371–83.CrossRefPubMed

16.

Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5, and 6. Aliment Pharmacol Ther. 2014;39:137–47.CrossRefPubMed

17.

Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62(5):1040–6.CrossRefPubMed

18.

Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63(3):581–5.CrossRefPubMed

19.

Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15(9):1049–54.CrossRefPubMedPubMedCentral

20.

Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015;385(9986):2502–9.CrossRefPubMed

21.

Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatol. 2015;62(1):79–86.CrossRef

22.

Wilson EM, Kattakuzhy S, Sidharthan S, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis. 2016;62(3):280–8.CrossRefPubMed

23.

Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatol. 2015;61(6):1793–7.CrossRef

24.

Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol. 2015;62(S2):S192.CrossRef

25.

Osinusi A, Marti M, Kohli A, et al. Sofosbuvir/ledipasvir in retreatment of HCV genotype-1 patients who previously failed sofosbuvir/ribavirin therapy. [Abstract 011.] 49th Annual Meeting of the European Association for the Study of the Liver (EASL). April 9–13, 2014a; London, United Kingdom.

26.

Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.CrossRefPubMed

27.

Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with Ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82.CrossRefPubMed

28.

Foster GR, Pianko S, Cooper C, et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study. [Abstract L05.] 50th Annual Meeting of the European Association for the Study of the Liver (EASL). April 22–26, 2015; Vienna, Austria.

29.

Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49(4):634 – 51.CrossRefPubMed

30.

Guidance HCV. Recommendations for Testing, Managing, and Treating Hepatitis C. https://www.hcvguidelines.org. Accessed 5 Jan 2018

31.

Morrison TB, Wieland ML, Cha SS, et al. Disparities in preventative health services among Somali immigrants and refugees. J Immigr Minor Health. 2012;14(6):968–74.CrossRefPubMed

32.

Nguyen GC, Thuluvath PJ. Racial disparity of liver disease: biological, cultural, or socioeconomic factors. Hepatol. 2008;47(3):1058–66.CrossRef

33.

U.S. Census Bureau (2009). American community survey. https://usa.ipums.org/usa/index.shtml. Accessed 11 Dec 2015

34.

Omland LH, Osler M, Jepsen P, et al. Socioeconomic status in HCV infected patients- risk and prognosis. Clin Epidemiol. 2013;5:163–72.CrossRefPubMedPubMedCentral

35.

Dalgard O, Jeanssen S, Skaug K, et al. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol. 2003;38(8):864–70.CrossRefPubMed

36.

Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.CrossRefPubMed

37.

Jin R, Cai L, Tan M, et al. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1. Am J Gastroenterol. 2012;107(11):1675–83.CrossRefPubMedPubMedCentral

Titel: Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community
Publikationsdatum: 25.05.2018
Erschienen in: Journal of Immigrant and Minority Health / Ausgabe 3/2019
Print ISSN: 1557-1912
Elektronische ISSN: 1557-1920
DOI: https://doi.org/10.1007/s10903-018-0758-x

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Guards in Prisons: A Risk Group for Latent Tuberculosis Infection

Asthma/COPD Disparities in Diagnosis and Basic Care Utilization Among Low-Income Primary Care Patients

Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India

Uptake of Gynecological Cancer Screening and Performance of Breast Self-Examination Among 50-Year-Old Migrant and Non-migrant Women in Germany: Results of a Cross-Sectional Study (InEMa)

Oral Health Challenges in Refugees from the Middle East and Africa: A Comparative Study

Bidimensional Acculturation and Psychological Distress in Pakistani Immigrant Women in Norway: A Cross-Sectional Study